Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes

N Engl J Med. 2022 Oct 20;387(16):1529-1530. doi: 10.1056/NEJMc2211623.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adolescent
  • Diabetes Mellitus, Type 2* / drug therapy
  • Glucagon-Like Peptides / adverse effects
  • Humans
  • Immunoglobulin Fc Fragments / adverse effects
  • Recombinant Fusion Proteins / adverse effects

Substances

  • dulaglutide
  • Glucagon-Like Peptides
  • Immunoglobulin Fc Fragments
  • Recombinant Fusion Proteins